Stock Ratings / Health Care / ALGS / options

MGX (24) ESLA (39) GNTA (50) EVAX (48) ⌘ Pro Terminal →

Aligos Therapeutics Inc. (ALGS) Options Positioning, Max Pain & Unusual Sweeps

$5.03 -2.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.00

Aligos Therapeutics Inc. (ALGS) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $31.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALGS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Aligos Therapeutics Inc. (NASDAQ: ALGS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $5.03 (-2.71% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALGS ranks #976 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALGS compare to MGX and ESLA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALGS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ALGS leads on earnings multiple (N/A) while ALGS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALGS?

▼

Per ALGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799448), Aligos Therapeutics Inc. generated $2.2M in revenue (-39.5% YoY), -$24.2M in net income, and -$82.5M in free cash flow against $88.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.00 (-0.68%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALGS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (22/100 Composite)

🔍 WHY ALGS SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+5/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.53-12.5% Next Q

Q2 (-2Q)

Grade E$4.84-3.9% Next Q

Q3 (-1Q)

Grade E$4.65+8.2% Next Q

Current

Grade E$5.03-11.4% Hist 90D α

Trajectory: E (30) → E (22)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALGS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALGS currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.53) and Max Pain ($5.28) forces dealer call-delta covering toward $14.37.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALGS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALGS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 22%NO 78%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ALGS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ALGS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALGS)

✓Walkthrough of ALGS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALGS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.89%▲ ASCENDING CHANNEL

2026-11-02O $5.17H $5.17L $5.03C $5.03VOL 47.2K

RES: $8.71SUP: $4.59SMA50: $5.53SMA200: $6.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALGS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALGS Butterfly Map → + Track ALGS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -39.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALGS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALGS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALGS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALGS)

Health Care Rank #976 of 1016 ⚔️ MGX vs ALGS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALGS vs. MGX, ESLA, GNTA, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aligos Therapeutics Inc. (ALGS) ranks #976 by composite RQD confidence (22/100, grade E) and #800 by equity capitalization ($31.4M). Within this direct 5-issuer industry benchmark cohort, ALGS leads on earnings valuation at N/A trailing P/E, while ALGS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ALGS at 22/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALGS ACTIVE Aligos Therapeutics Inc.	E	22/100	—	—	-35.0%	-2.71%	$31.4M	Benchmark Subject
MGX Metagenomi Therapeutics Inc.	E	24/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-algs →
ESLA Estrella Immunopharma Inc.	D-	39/100	—	—	-35.0%	-11.32%	$31.7M	/esla-vs-algs →
GNTA Genenta Science S.p.A.	D	50/100	—	—	—	+2.48%	$29.9M	/gnta-vs-algs →
EVAX Evaxion A/S	D	48/100	—	—	—	-0.96%	$27.8M	/evax-vs-algs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799448

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aligos Therapeutics Inc. (ALGS) reported GAAP revenue of $2.2M (-39.5% vs. FY2024 revenue of $3.6M , and -64.7% cumulative change since FY2023) , GAAP net income of -$24.2M, operating cash flow of -$82.5M, and free cash flow of -$82.5M (-2.0% YoY). On the balance sheet, ALGS closed FY2025 with $88.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.2M	-$24.2M	-$82.5M	-$82.5M	$88.5M	—
FY2024 (FY)	2024-12-31	$3.6M	-$131.2M	-$80.7M	-$80.9M	$70.1M	—
FY2023 (FY)	2023-12-31	$6.2M	-$87.7M	-$79.0M	-$79.0M	—	—

3. ALGS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALGS compare to MGX and ESLA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALGS?

Where is ALGS trading relative to its 50-day, 200-day, and 52-week technical levels?

ALGS last traded at $5.03 (-2.71% on volume of 47,209 shares), positioning the stock -9.04% below its 50-day simple moving average ($5.53) and -19.13% below its 200-day simple moving average ($6.22). Across its 52-week range of $3.98 to $13.69, ALGS sits at the 10.8% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.40 to $5.66).

ALGS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ALGS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ALGS.

Direct Sub-Reports: ALGS RQD Cockpit ALGS 12M Forecast ALGS Earnings & Move ALGS Dividends & DRIP ALGS Insiders & 13F ALGS Whale Options ALGS Profit Sankey ALGS News & Why